Trial Condition(s):

Atrial Fibrillation

Real-world comparative effectiveness of Rivaroxaban versus VKA (RIVA-F)

Bayer Identifier:

18734

ClinicalTrials.gov Identifier:

NCT02690155

EudraCT Number:

Not Available

Study Completed

Trial Purpose

To obtain a better understanding on the comparative effectiveness of rivaroxaban versus VKA(Vitamin K antagonist) for stroke prevention in patients with NVAF(non-valvular atrial fibrillation) in a real-life setting

Inclusion Criteria
-NVAF(non-valvular atrial fibrillation) will be defined as the occurrence of 2 or more inpatient or outpatient
claims with ICD(International Classification of Disease)-9 427.31 as the diagnosis code at any time in the patient’s
data history prior to inclusion
-Patients will be required to have 180 days of enrollment for the assessment of baseline characteristics
-CHA2DS2-Vasc score ≥2 during the 180 days prior to index rivaroxaban use baseline period (CHA2DS2-Vasc: Diabetes mellitus; S2: prior Stroke or TIA or Thromboembolism; V: Vascular disease; A: Age 65–74 years; Sc: Sex category)
Exclusion Criteria
-Patients <18 years of age
-Patients with valvular AF (Atrial fibrillation)
-Pregnancy
-Malignant cancers
-Transient cause of AF
-Patients with venous thromboembolism (pulmonary embolism or deep vein thrombosis)
-Patients with major surgery defined as hip or knee replacement
-Prescriptions of oral anticoagulants (OACs) (apixaban, warfarin, dabigatran, rivaroxaban) before index date
-Prescription of more than one OAC on the index date
-Patient with any of the events defined in the composite endpoint
--Fatal bleeding
--Fatal Stroke/Myocardial infarction
--Intracranial hemorrhage
--Ischemic stroke
--Myocardial infarction

Trial Summary

Enrollment Goal
38831
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Xarelto (Rivaroxaban, BAY59-7939)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

New York, United States

Status
Active, not recruiting
 

Trial Design